FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Myron Czuczman

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Oliver W Press; Lisa M Rimsza; Catherine Spier; Joseph M Unger; Rita M Braziel; Bruce D Cheson; Myron S Czuczman; Shaker R Dakhil; Jonathan W Friedberg; Ajay K Gopal; Mark S Kaminski; Michael LeBlanc; David G Maloney; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Myron S Czuczman; E D Hsi; J L Johnson; S Jung; J P Leonard; John C Byrd; Bruce D Cheson
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Neil H Bander; Myron S Czuczman; Anas Younes
Antibody-drug conjugate technology development for hematologic disorders.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Myron Czuczman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Oliver W Press; Lisa M Rimsza; Catherine Spier; Joseph M Unger; Rita M Braziel; Bruce D Cheson; Myron S Czuczman; Shaker R Dakhil; Jonathan W Friedberg; Ajay K Gopal; Mark S Kaminski; Michael LeBlanc; David G Maloney; Thomas P Miller; Richard I Fisher
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):314-20.
2012: Myron S Czuczman; E D Hsi; J L Johnson; S Jung; J P Leonard; John C Byrd; Bruce D Cheson
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(9):2356-62.
2012: Neil H Bander; Myron S Czuczman; Anas Younes
Antibody-drug conjugate technology development for hematologic disorders.
Clinical advances in hematology & oncology : H&O 2012;10(8 Suppl 10):1-16.
2012: Gregory A Abel; Allison L Crosby; Myron S Czuczman; Jonathan W Friedberg; Leo I Gordon; Michael Millenson; Joyce C Niland; Maria A Rodriguez; Ann Vanderplas; Andrew D Zelenetz; Ann S LaCasce
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database.
Leukemia & lymphoma 2012;53(6):1113-6.
2012: Anita Kumar; Ann S LaCasce; Eva Lepisto; Michael Millenson; Auayporn Nademanee; Joyce Niland; Maria A Rodriguez; Ann Vanderplas; Andrew D Zelenetz; Allison L Crosby; Myron S Czuczman; Jonathan W Friedberg; Leo I Gordon; Gregory A Abel
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Cancer 2012;118(11):2944-51.
2012: Myron S Czuczman; Ole V Gadeberg; Nancy Goldstein; Ira Gupta; Georg Hess; Roxanne C Jewell; Thomas S Lin; Steen Lisby; Lars M Pedersen; Claus Strange; Andreas Viardot; Kristian Windfeld
Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma.
British journal of haematology 2012;157(4):438-45.
2012: Myron S Czuczman; Vincent Delwail; Christine G DiRienzo; Luis Fayad; Eve Gallop-Evans; Nancy Goldstein; Ira Gupta; Anton Hagenbeek; Andrzej Hellmann; Eric Jacobsen; Roxanne C Jewell; Kazimierz Kuliczkowski; Thomas S Lin; Brian K Link; Steen Lisby; Lauren Pinter-Brown; John Radford; Charlotte A Russell; Martin Schultz; Guillaume Cartron
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Blood 2012;119(16):3698-704.
2012: Ann S LaCasce; Eva M Lepisto; Michael Millenson; Auayporn P Nademanee; Joyce Niland; Maria A Rodriguez; Jonathan L Vandergrift; Ann Vanderplas; Andrew D Zelenetz; Gregory A Abel; Douglas W Blayney; Allison L Crosby; Myron S Czuczman; Leo I Gordon; Jonathan W Friedberg
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
Blood 2012;119(9):2093-9.
2012: Ping-Chiao Tsai; Naveen Bangia; Francisco J Hernandez-Ilizaliturri; Scott H Olejniczak; Myron S Czuczman
Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(4):1039-50.
2012: Matthew J Barth; George Deeb; John F Gibbs; Francisco J Hernandez-Ilizaliturri; Cory Mavis; Ping-Chiao Tsai; Myron S Czuczman
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma.
British journal of haematology 2012;156(4):490-8.
2011: Francisco J Hernandez-Ilizaliturri; William R Macon; Farhana Malik; Stefano A Pileri; Thomas E Witzig; Pier L Zinzani; George Deeb; Andre Goy; Myron S Czuczman
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Cancer 2011;117(22):5058-66.
2011: Asher Chanan-Khan; Kasyapa Chitta; Myron S Czuczman; Noreen Ersing; Kelvin Lee; Terry L Mashtare; Aisha Masood; Aneel Paulus; Taimur Sher; Abhisek Swaika; Paul K Wallace; Greg Wilding; Ivan Borrello; Naveen Bangia
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
British journal of haematology 2011;155(4):457-67.
2011: Lyudmyla Derby; Myron S Czuczman
Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.
Future oncology (London, England) 2011;7(8):963-79.
2011: Myron S Czuczman; Annetti Ervin-Haynes; Ju Li; Dennis Pietronigro; Jonathan Polikoff; Julie M Vose; Thomas E Witzig; Pier L Zinzani; Rena Buckstein; Craig B Reeder
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
British journal of haematology 2011;154(4):477-81.
2011: Taimur Sher; Saif Soniwala; Raman Sood; Wei Tan; Gregory Wilding; Margaret Wood; Sikander Ailawadhi; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri; Fredrick Hong; Daniel Iancu; Saad Jamshed; William Lawrence; Kelvin Lee; Debbie Manfredi; Aisha Masood; Kena C Miller; Asher Chanan-Khan
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients.
British journal of haematology 2011;154(1):104-10.
2011: Elizabeth A Brem; Karen Thudium; Sapna Khubchandani; Ping-Chiao Tsai; Scott H Olejniczak; Seema Bhat; Wasif Riaz; Jenny Gu; Arshad Iqbal; Ryan Campagna; Joy Knight; Cory Mavis; Paul Hoskin; George Deeb; John F Gibbs; Gerald Fetterly; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas.
British journal of haematology 2011;153(5):599-611.
2011: Asher Chanan-Khan; Kena C Miller; David Lawrence; Swaminathan Padmanabhan; Austin Miller; Francisco Hernandez-Illatazurri; Myron S Czuczman; Paul K Wallace; Jerome B Zeldis; Kelvin Lee
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.
Cancer 2011;117(10):2127-35.
2011: Andrew D Zelenetz; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C Byrd; Myron S Czuczman; Luis E Fayad; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Barbara Pro; Nashitha Reddy; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; William G Wierda; Joachim Yahalom; Nadeem Zafar
Non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(5):484-560.
2010: Scott H Olejniczak; Jennifer Blickwedehl; Alan Belicha-Villanueva; Naveen Bangia; Wasif Riaz; Cory Mavis; James L Clements; John Gibbs; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells.
Blood 2010;116(25):5605-14.
2010: Anas Younes; Julie M Vose; Andrew D Zelenetz; M R Smith; H A Burris; S M Ansell; J Klein; W Halpern; R Miceli; E Kumm; N L Fox; Myron S Czuczman
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.
British journal of cancer 2010;103(12):1783-7.
2010: Wyndham H Wilson; Owen A O'Connor; Myron S Czuczman; Ann S LaCasce; John Gerecitano; John P Leonard; Anil Tulpule; Kieron Dunleavy; Hao Xiong; Yi-Lin Chiu; Yue Cui; Todd Busman; Steven W Elmore; Saul H Rosenberg; Andrew Krivoshik; Sari H Enschede; Rod A Humerickhouse
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
The lancet oncology 2010;11(12):1149-59.
2010: N Reddy; Myron S Czuczman
Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(9):1756-64.
2010: Myron S Czuczman; David J Straus; John Gribben; Henning Bredenfeld; Jonathan Friedberg; Catherine Bollard
Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas.
Leukemia & lymphoma 2010;51 Suppl 1():41-9.
2010: Myron S Czuczman; Stephanie A Gregory
The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Leukemia & lymphoma 2010;51(6):983-94.
2010: Anjali Advani; Bertrand Coiffier; Myron S Czuczman; Martin Dreyling; James Foran; Eva Gine; Christian Gisselbrecht; Nicolas Ketterer; Sunita Nasta; Ama Rohatiner; Ingo G H Schmidt-Wolf; Martin Schuler; Jorge Sierra; Mitchell R Smith; Gregor Verhoef; Jane N Winter; Joseph Boni; Erik Vandendries; Mark Shapiro; Luis Fayad
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(12):2085-93.
2010: Myron S Czuczman; John P Leonard; Michael E Williams
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
Clinical advances in hematology & oncology : H&O 2010;8(4):A1-14; quiz A15.
2010: Myron S Czuczman; John P Leonard; Michael E Williams
Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.
Clinical advances in hematology & oncology : H&O 2010;8(4 Suppl 8):1-14; quiz 2p following page 14.
2010: Andrew D Zelenetz; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; John C Byrd; Myron S Czuczman; Luis Fayad; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven Horwitz; Mark S Kaminski; Youn H Kim; Ann S LaCasce; Tariq I Mughal; Auyporn Nademanee; Pierluigi Porcu; Oliver Press; Leonard Prosnitz; Nashitha Reddy; Mitchell R Smith; Lubomir Sokol; Lode Swinnen; Julie M Vose; William G Wierda; Joachim Yahalom; Furhan Yunus
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(3):288-334.
2010: Seema Bhat; Myron S Czuczman
Galiximab: a review.
Expert opinion on biological therapy 2010;10(3):451-8.
2010: Wasif Riaz; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms.
Immunologic research 2010;46(1-3):192-205.
2010: Myron S Czuczman; Mathias J Rummel
Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana.
Clinical advances in hematology & oncology : H&O 2010;8(2):A1-11.
2010: Taimur Sher; Kena C Miller; David Lawrence; Amy Whitworth; Francisco J Hernandez-Ilizaliturri; Myron S Czuczman; Austin Miller; William Lawrence; Syed Ali Bilgrami; Raman Sood; Margaret T Wood; AnneMarie W Block; Kelvin Lee; Asher Chanan-Khan
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Leukemia & lymphoma 2010;51(1):85-8.
2010: Brad S Kahl; Nancy L Bartlett; John P Leonard; Ling Chen; Kristen Ganjoo; Michael E Williams; Myron S Czuczman; K Sue Robinson; Robin Joyce; Richard H van der Jagt; Bruce D Cheson
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.
Cancer 2010;116(1):106-14.
2009: S A Bhat; Myron S Czuczman
Novel antibodies in the treatment of non-Hodgkin's lymphoma.
The Netherlands journal of medicine 2009;67(8):311-21.
2009: Jerald P Radich; Andrew D Zelenetz; Wing C Chan; Carlo M Croce; Myron S Czuczman; Harry P Erba; Sandra J Horning; Jane Houldsworth; B Douglas Smith; David S Snyder; Hema M Sundar; Meir Wetzler; Jane N Winter
NCCN task force report: molecular markers in leukemias and lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7 Suppl 4():S1-34, quiz S35-6.
2009: Asher Chanan-Khan; Kena C Miller; Laurie Musial; Swaminathan Padmanabhan; Jihnhee Yu; Sikander Ailawadhi; Taimur Sher; Alice Mohr; Zale P Bernstein; Maurice Barcos; Mehul Patel; Dan Iancu; Kelvin Lee; Myron S Czuczman
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial.
Leukemia & lymphoma 2009;50(7):1096-101.
2009: Kieron Dunleavy; Stefania Pittaluga; Myron S Czuczman; Sandeep S Dave; George Wright; Nicole Grant; Margaret Shovlin; Elaine S Jaffe; John Janik; Louis M Staudt; Wyndham H Wilson
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Blood 2009;113(24):6069-76.
2009: Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies.
Oncology (Williston Park, N.Y.) 2009;23(7):610-5.
2009: Sapna Khubchandani; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Current opinion in investigational drugs (London, England : 2000) 2009;10(6):579-87.
2009: Francisco J Hernandez-Ilizaliturri; Myron S Czuczman
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
Oncology (Williston Park, N.Y.) 2009;23(6):546-53.
2009: David M Goldenberg; Edmund A Rossi; Rhona Stein; Thomas M Cardillo; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri; Hans J Hansen; Chien-Hsing Chang
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
Blood 2009;113(5):1062-70.
2008: Ann S LaCasce; Michelle E Kho; Jonathan W Friedberg; Joyce C Niland; Gregory A Abel; Maria Alma Rodriguez; Myron S Czuczman; Michael M Millenson; Andrew D Zelenetz; Jane C Weeks
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(31):5107-12.
2008: Sanjay Vinjamaram; Myron S Czuczman; Francisco J Hernandez-Ilizaliturri
The use of galiximab in non-Hodgkin lymphoma.
Clinical lymphoma & myeloma 2008;8(5):277-82.
2008: M Jules Mattes; Robert M Sharkey; Habibe Karacay; Myron S Czuczman; David M Goldenberg
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):6154-60.
2008: Andrew D Zelenetz; Ranjana H Advani; John C Byrd; Myron S Czuczman; Lloyd E Damon; Madeleine Duvic; Luis Fayad; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Steven Horwitz; Mark S Kaminski; Youn H Kim; Ann S LaCasce; Auyporn Nademanee; Elise A Olsen; Pierluigi Porcu; Oliver Press; Leonard R Prosnitz; Mitchell R Smith; Eduardo M Sotomayor; Julie M Vose; Joachim Yahalom; Furhan Yunus
Non-Hodgkin's lymphomas.
Journal of the National Comprehensive Cancer Network : JNCCN 2008;6(4):356-421.
2008: Myron S Czuczman; Scott Olejniczak; Aruna Gowda; Adam Kotowski; Arvinder Binder; Harman Kaur; Joy Knight; Petr Starostik; Julie Deans; Francisco J Hernandez-Ilizaliturri
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1561-70.
2008: Scott H Olejniczak; Francisco J Hernandez-Ilizaliturri; James L Clements; Myron S Czuczman
Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1550-60.
2008: Owen A O'Connor; Myron S Czuczman
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Leukemia & lymphoma 2008;49 Suppl 1():59-66.
2008: Myron S Czuczman
Sixth International Workshop on non-Hodgkin Lymphoma: 16-17 November 2007, Boston, USA.
Leukemia & lymphoma 2008;49 Suppl 1():4-6.
2008: Nishitha Reddy; Francisco J Hernandez-Ilizaliturri; George Deeb; Mark Roth; Mary Vaughn; Joy Knight; Paul Wallace; Myron S Czuczman
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
British journal of haematology 2008;140(1):36-45.
2007: Raymond I Cruz; Francisco J Hernandez-Ilizaliturri; Scott Olejniczak; George Deeb; Joy Knight; Paul Wallace; Beth L Thurberg; William Kennedy; Myron S Czuczman
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Leukemia & lymphoma 2007;48(12):2424-36.
2007: Myron S Czuczman; Christos Emmanouilides; Mohamed Darif; Thomas E Witzig; Leo I Gordon; Stephen Revell; Katie Vo; Arturo Molina
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4285-92.
2007: Sreeram Maddipatla; Francisco J Hernandez-Ilizaliturri; Joy Knight; Myron S Czuczman
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4556-64.
2007: Donald A Podoloff; Ranjana Advani; Craig Allred; Al B Benson; Elizabeth Brown; Harold J Burstein; Robert W Carlson; R Edward Coleman; Myron S Czuczman; Dominique Delbeke; Stephen B Edge; David S Ettinger; Frederic W Grannis; bruce hillner; John M Hoffman; Krystyna Kiel; Ritsuko Komaki; Steven M Larson; David A Mankoff; Kenneth E Rosenzweig; John M Skibber; Joachim Yahalom; Jq Michael Yu; Andrew D Zelenetz
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5 Suppl 1():S1-22; quiz S23-2.
2007: Steven Cai; Francis Cannizzo; Kelli M Bullard Dunn; John F Gibbs; Myron S Czuczman; Ashwani Rajput
The role of surgical intervention in non-Hodgkin's lymphoma of the colon and rectum.
American journal of surgery 2007;193(3):409-12; discussion 412.
2007: Myron S Czuczman; Pierluigi Porcu; Jeffrey Johnson; Donna Niedzwiecki; Michael Kelly; Eric D Hsi; James R Cook; George P Canellos; Bruce D Cheson
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
Leukemia & lymphoma 2007;48(1):97-103.
2006: Asher Chanan-Khan; Kena C Miller; Laurie Musial; David S Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David E Spaner; Alice Mohr; Catriona Byrne; Francisco J Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(34):5343-9.
2006: David J Straus; Marcia A Testa; Brenda J Sarokhan; Myron S Czuczman; Anil Tulpule; Ralph R Turner; Shirley A Riggs
Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
Cancer 2006;107(8):1909-17.
2006: Myron S Czuczman; Antonio J Grillo-López; Baha Alkuzweny; Robin Weaver; A Larocca; P McLaughlin
Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
Leukemia & lymphoma 2006;47(9):1830-40.
2006: Andrew D Zelenetz; Ranjana Advani; Francis Buadi; Fernando Cabanillas; Michael A Caligiuri; Myron S Czuczman; Lloyd E Damon; Luis Fayad; Ian W Flinn; Andres Forero; Martha J Glenn; Jon P Gockerman; Leo I Gordon; Nancy Lee Harris; Richard T Hoppe; Mark S Kaminski; Ann S LaCasce; Auyporn Nademanee; Pierluigi Porcu; Oliver W Press; Leonard R Prosnitz; Mitchell R Smith; Eduardo M Sotomayor; Julie M Vose; Joachim Yahalom
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(3):258-310.
2006: Myron S Czuczman
Controversies in follicular lymphoma: "who, what, when, where, and why?" (not necessarily in that order!).
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2006;():303-10.
2006: Scott H Olejniczak; Carleton C Stewart; Kathleen A Donohue; Myron S Czuczman
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.
Immunological investigations 2006;35(1):93-114.
2005: Francisco J Hernandez-Ilizaliturri; Venkata Jupudy; Scott Reising; Elizabeth A Repasky; Myron S Czuczman
Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.
Leukemia & lymphoma 2005;46(12):1775-84.
2005: Asher Chanan-Khan; Kena C Miller; Kenichi Takeshita; Alexandra Koryzna; Kathleen A Donohue; Zale P Bernstein; Alice Mohr; Donald Klippenstein; Paul Wallace; Jerome B Zeldis; Christine Berger; Myron S Czuczman
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Blood 2005;106(10):3348-52.
2005: Julie M Vose; B K Link; M L Grossbard; Myron S Czuczman; A Grillo-Lopez; Richard I Fisher
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Leukemia & lymphoma 2005;46(11):1569-73.
2005: Francisco J Hernandez-Ilizaliturri; Nishitha Reddy; Beata Holkova; Edris Ottman; Myron S Czuczman
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5984-92.
2005: Myron S Czuczman; Aron Thall; Thomas E Witzig; Julie M Vose; Anas Younes; Christos Emmanouilides; Thomas P Miller; Joseph O Moore; John P Leonard; Leo I Gordon; John Sweetenham; Baha Alkuzweny; Deborah M Finucane; Bryan R Leigh
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4390-8.
2005: Julie A Baker; Joli R Weiss; Myron S Czuczman; Ravi J Menezes; Christine B Ambrosone; Kirsten B Moysich
Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma.
Cancer causes & control : CCC 2005;16(3):301-8.
2005: Theresa Hahn; Mustafa Benekli; C Wong; Kirsten B Moysich; Andrew Hyland; Arthur M Michalek; Arif Alam; Maria R Baer; Barbara Bambach; Myron S Czuczman; Meir Wetzler; Joanne L Becker; Philip L McCarthy
A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
Bone marrow transplantation 2005;35(6):557-66.
2005: Aasma Shaukat; Faris Bakri; Paul Young; Theresa Hahn; Donna Ball; Maria R Baer; Meir Wetzler; James L Slack; Peter Loud; Myron S Czuczman; Philip L McCarthy; THOMAS WALSH; Brahm H Segal
Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics.
Mycopathologia 2005;159(2):181-8.
2005: Myron S Czuczman; A Koryzna; Alice Mohr; Carleton Stewart; Kathleen A Donohue; LE Blumenson; Zale P Bernstein; Philip McCarthy; Arif Alam; Francisco J Hernandez-Ilizaliturri; M Skipper; Karen Brown; Asher Chanan-Khan; Donald Klippenstein; Peter A Loud; M K Rock; Mark Benyunes; A Grillo-Lopez; Steven H Bernstein
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):694-704.
2005: Rina Kansal; Sheila N J Sait; AnneMarie W Block; Pamela M Ward; Felicity L R Kelly; Richard T Cheney; Myron S Czuczman; Martin L Brecher; Maurice Barcos
Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(2):235-43.
2004: Stephen M Ansell; Russell J Schilder; Peter C Pieslor; Leo I Gordon; Christos Emmanouilides; Katie Vo; Myron S Czuczman; Thomas E Witzig; Charles Theuer; Arturo Molina
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Clinical lymphoma 2004;5(3):202-4.
2004: Jeyanthi Ramanarayanan; Francisco J Hernandez-Ilizaliturri; Asher Chanan-Khan; Myron S Czuczman
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
British journal of haematology 2004;127(5):519-30.
2004: Myron S Czuczman; Robin Weaver; Baha Alkuzweny; Judy Berlfein; Antonio J Grillo-López
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4711-6.
2004: Theresa Hahn; Arif Raza Alam; David S Lawrence; Laurieann Ford; Maria R Baer; Barbara Bambach; Zale P Bernstein; Myron S Czuczman; Joaquin Silva; James L Slack; Meir Wetzler; Joanne Becker; Philip L McCarthy
Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion.
Transplantation 2004;78(10):1515-22.
2004: Myron S Czuczman
Update: NCCN non-Hodgkin's lymphoma clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2 Suppl 3():S-46-52.
2004: Francisco J Hernandez-Ilizaliturri; Aruna Gowda; Myron S Czuczman
Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Clinical advances in hematology & oncology : H&O 2004;2(9):606-18.
2004: Leo I Gordon; Thomas E Witzig; Arturo Molina; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Katie Vo; Charles Theuer; Brad Pohlman; Nancy L Bartlett; Gregory A Wiseman; Mohamed Darif; Christine White
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Clinical lymphoma 2004;5(2):98-101.
2004: Asher Chanan-Khan; Tariq Islam; Arif Alam; Kena C Miller; John Gibbs; Maurice Barcos; Myron S Czuczman; Pamela Paplham; Theresa Hahn; Philip McCarthy
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
Leukemia & lymphoma 2004;45(8):1673-5.
2004: Asher Chanan-Khan; Myron S Czuczman
Bcl-2 antisense therapy in B-cell malignant proliferative disorders.
Current treatment options in oncology 2004;5(4):261-7.
2004: Asher Chanan-Khan; Sridhar Srinivasan; Myron S Czuczman
Prevention and management of cardiotoxicity from antineoplastic therapy.
The journal of supportive oncology 2004;2(3):251-6; discussion 259-61, 264-6.
2004: Sridhar Srinivasan; Kenichi Takeshita; Beata Holkova; Myron S Czuczman; Kena Miller; Zale P Bernstein; Deborah Driscoll; Asher Chanan-Khan
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART.
HIV clinical trials 2004;5(3):140-5.
2003: Francisco J Hernandez-Ilizaliturri; Venkata Jupudy; Julie R Ostberg; Ezogelin Oflazoglu; Amy Huberman; Elizabeth A Repasky; Myron S Czuczman
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):5866-73.
2003: Robert M Sharkey; Arnold Brenner; Jack Burton; George Hajjar; Stephen P Toder; Abass Alavi; Alexander Matthies; Donald E Tsai; Stephen J Schuster; Edward A Stadtmauer; Myron S Czuczman; Dominick Lamonica; Françoise Kraeber-Bodere; Beatrice Mahe; Jean-François Chatal; André Rogatko; George Mardirrosian; David M Goldenberg
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(12):2000-18.
2003: Theresa Hahn; Steven Neil Wolff; Myron S Czuczman; Richard I Fisher; Hillard M Lazarus; Philip L McCarthy; Julie M Vose; Lisa Warren; Richard Watt
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(10):667.
2003: Theresa Hahn; C Rondeau; Aasma Shaukat; Venkata Jupudy; A Miller; Arif Raza Alam; Maria R Baer; Barbara Bambach; Zale P Bernstein; Asher Chanan-Khan; Myron S Czuczman; J Slack; Meir Wetzler; B K Mookerjee; J Silva; Philip L McCarthy
Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients.
Bone marrow transplantation 2003;32(4):405-10.
2003: Mustafa Benekli; Theresa Hahn; F Shafi; A Qureshi; Arif Raza Alam; Myron S Czuczman; Zale P Bernstein; Asher Chanan-Khan; Joanne L Becker; Philip L McCarthy
Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients.
Bone marrow transplantation 2003;32(2):139-43.
2003: Myron S Czuczman; Pier Luigi Zinzani
The first International Workshop on Non-Hodgkin's Lymphoma: taking a close look at current issues and future developments.
Leukemia & lymphoma 2003;44 Suppl 3():S1-4.
2002: Dominick Lamonica; Myron S Czuczman; Hani A Nabi; Donald Klippenstein; Z Grossman
Radioimmunoscintigraphy (RIS) with bectumomab (Tc99m labeled IMMU-LL2, Lymphoscan) in the assessment of recurrent non-Hodgkin's lymphoma (NHL).
Cancer biotherapy & radiopharmaceuticals 2002;17(6):689-97.
2002: Kevin R Imrie; David C Linch; Myron S Czuczman
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma.
Anti-cancer drugs 2002;13 Suppl 2():S19-24.
2002: Anton Hagenbeek; Myron S Czuczman; Michele Ghielmini; Michael Herold; Eva Kimby; Philippe Solal-Céligny; Michael Unterhalt
Rituximab therapy for indolent non-Hodgkin's lymphoma.
Anti-cancer drugs 2002;13 Suppl 2():S11-7.
2002: Asher Chanan-Khan; Myron S Czuczman
Radioimmunotherapy in non-Hodgkin lymphoma.
Current opinion in oncology 2002;14(5):484-9.
2002: Thomas E Witzig; Ian W Flinn; Leo I Gordon; Christos Emmanouilides; Myron S Czuczman; Mansoor N Saleh; Larry D Cripe; Gregory A Wiseman; Teresa Olejnik; Pratik Multani; Christine White
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3262-9.
2002: Thomas E Witzig; Leo I Gordon; Fernando Cabanillas; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Brad L Pohlman; Nancy L Bartlett; Gregory A Wiseman; Norman Padre; Antonio J Grillo-López; Pratik Multani; Christine White
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(10):2453-63.
2002: Myron S Czuczman
Immunochemotherapy in indolent non-Hodgkin's lymphoma.
Seminars in oncology 2002;29(2 Suppl 6):11-7.
2002: Leo I Gordon; Thomas E Witzig; Gregory A Wiseman; Ian W Flinn; Stewart Spies; Daniel H S Silverman; Christos Emmanouilides; Larry D Cripe; Mansoor Saleh; Myron S Czuczman; Teresa Olejnik; Christine White; Antonio J Grillo-López; Christos Emmanuolides
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Seminars in oncology 2002;29(1 Suppl 2):87-92.
2002: Myron S Czuczman; Alexandra Fallon; Alice Mohr; Carleton Stewart; Zale P Bernstein; Philip McCarthy; Marion Skipper; Karen Brown; Kena Miller; Diane Wentling; Donald Klippenstein; Peter A Loud; Mike K Rock; Mark Benyunes; Antonio J Grillo-López; Steven H Bernstein
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Seminars in oncology 2002;29(1 Suppl 2):36-40.
2001: Myron S Czuczman
Combination chemotherapy and rituximab.
Anti-cancer drugs 2001;12 Suppl 2():S15-9.
2001: Nikhil I Khushalani; Faris Bakri; Diane Wentling; Karen Brown; Alice Mohr; Barbara Anderson; C Keesler; Donna Ball; Zale P Bernstein; Steven H Bernstein; Myron S Czuczman; B H Segal; Philip L McCarthy
Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review.
Bone marrow transplantation 2001;27(10):1071-3.
2001: A Khorana; P Bunn; P McLaughlin; Julie M Vose; Carleton Stewart; Myron S Czuczman
A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Leukemia & lymphoma 2001;41(1-2):77-87.
2001: M Simon; Theresa Hahn; Laurie A Ford; Barbara Anderson; D Swinnich; Maria R Baer; Barbara Bambach; Steven H Bernstein; Zale P Bernstein; Myron S Czuczman; James L Slack; Meir Wetzler; Geoffrey P Herzig; JR Schriber; Philip L McCarthy
Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
Bone marrow transplantation 2001;27(6):627-33.
2001: Julie M Vose; B K Link; M L Grossbard; Myron S Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; Richard I Fisher
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):389-97.
2001: Theresa Hahn; Steven Neil Wolff; Myron S Czuczman; Richard I Fisher; Hillard M Lazarus; Julie M Vose; L Warren; R Watt; Philip L McCarthy
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2001;7(6):308-31.
2001: Myron S Czuczman; Antonio J Grillo-López; P McLaughlin; Christine White; M Saleh; L Gordon; Albert F LoBuglio; J Rosenberg; Baha Alkuzweny; D Maloney
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(1):109-14.
2000: Thomas A Davis; Antonio J Grillo-López; Christine White; P McLaughlin; Myron S Czuczman; B K Link; DG Maloney; R L Weaver; J Rosenberg; Ronald Levy
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(17):3135-43.
2000: Mustafa Benekli; Barbara Anderson; Diane Wentling; S Bernstein; Myron S Czuczman; Philip McCarthy
Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis.
Bone marrow transplantation 2000;25(12):1299-301.
1999: Myron S Czuczman
CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
Seminars in oncology 1999;26(5 Suppl 14):88-96.
1999: Lawrence D Piro; Christine White; Antonio J Grillo-López; N Janakiraman; Alan Saven; T M Beck; CL Varns; S Shuey; Myron S Czuczman; J W Lynch; J E Kolitz; V Jain
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(6):655-61.
1999: Myron S Czuczman; Richard K Dodge; Carleton C Stewart; Stanley R Frankel; Frederick R Davey; Bayard L Powell; Ted P Szatrowski; Charles Alan Schiffer; Richard A Larson; Clara D Bloomfield
Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364.
Blood 1999;93(11):3931-9.
1999: A Alidina; David S Lawrence; Laurie A Ford; Maria R Baer; Barbara Bambach; Steven H Bernstein; Myron S Czuczman; James L Slack; Edward Spangenthal; Meir Wetzler; Maurice Barcos; Gary M Proulx; Barbara Anderson; Philip L McCarthy
Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1999;5(5):322-7.
1999: Myron S Czuczman; Antonio J Grillo-López; Christine White; M Saleh; L Gordon; Albert F LoBuglio; C Jonas; Donald Klippenstein; BK Dallaire; CL Varns
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):268-76.
1998: G A Leget; Myron S Czuczman
Use of rituximab, the new FDA-approved antibody.
Current opinion in oncology 1998;10(6):548-51.
1998: Neil L Berinstein; Antonio J Grillo-López; Christine White; I Bence-Bruckler; D Maloney; Myron S Czuczman; D Green; J Rosenberg; P McLaughlin; D Shen
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(9):995-1001.
1998: Peter McLaughlin; Antonio J Grillo-López; B K Link; Ronald Levy; Myron S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; Christine White; Fernando Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; BK Dallaire
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2825-33.